Document:

Project Agreement No. 2

 Exhibit 10.2 
 PROJECT AGREEMENT No. 2 
 BETWEEN 
 VIROPHARMA INCORPORATED 
 AND 
 OSG NORWICH PHARMACEUTICALS, INC. 
 (Vancocin) 

 TABLE OF CONTENTS: 
  

					
	PROJECT AGREEMENT	  	3
	1.	  	Identification of Terms.	  	3
	2.	  	Development Activities.	  	4
	3.	  	Equipment Purchase.	  	5
	4.	  	Manufacture of Product.	  	6
	5.	  	Manufacturing Price.	  	9
	6.	  	Shelf Life and Storage Requirements.	  	10
	7.	  	Term.	  	10
	8.	  	Entire Agreement.	  	12
	9.	  	Amendment.	  	12
	PRICE EXHIBIT	  	14
	DEVELOPMENT PLAN EXHIBIT	  	17
	SCHEDULE OF EXCEPTIONS	  	19
	MATERIALS EXHIBIT	  	20

 PROJECT AGREEMENT No. 2 
 VIROPHARMA INCORPORATED (“ViroPharma”) and OSG NORWICH PHARMACEUTICALS, INC. (“OSG Norwich”) are entering into this Project Agreement
No. 2 (“Project Agreement”) effective as of the 15th day of May 2006 (the “Project Agreement
Effective Date”). 
 ViroPharma and OSG Norwich agree that this Project Agreement is entered into pursuant to the Master Agreement (the
“Agreement”) and the Quality Agreement between ViroPharma and OSG Norwich dated as of December 1, 2005. The project described herein, for the purpose of increasing the batch size of the production of Vancocin 125mg and 250mg capsules,
shall be governed by the terms, conditions and obligations set forth in the Agreement and this Project Agreement, and the terms of the Agreement are hereby incorporated into this Project Agreement by reference. Notwithstanding the incorporation by
reference of the Agreement into this Project Agreement, in the event of conflict between the terms, conditions and obligations of this Project Agreement and the Agreement, the terms, conditions and obligations of this Project Agreement shall govern.
Capitalized terms not otherwise defined herein shall have the meaning given them in the Agreement. In addition to the foregoing, the Parties hereby agree as follows: 
  

	 	1.	Identification of Terms. 

 For purposes of this
Project Agreement, the following terms defined in the Agreement shall be further defined as follows: 
  

	 	(a)	Active Pharmaceutical Ingredient. “Active Pharmaceutical Ingredient” or “API” shall mean bulk Vancomycin Hydrochloride. 

  

	 	(b)	API Reimbursement Price. “API Reimbursement Price,” in U.S. dollars, is the average per batch of Product price paid by ViroPharma to a third party for API during
the Calendar Quarter in which the price is being calculated. 

  

	 	(c)	Commencement Date. “Commencement Date” shall mean the date that both parties agree in writing that the Development Plan has been successfully completed and has
resulted in a validated process for Manufacturing the Product. 

  

	 	(d)	Commercial Manufacturing Initiation. “Commercial Manufacturing Initiation” shall mean the completion of Development Plan and the start of manufacturing Product by
OSG Norwich for commercial sale and shall commence following the Commencement Date on the date the first post-validation lot is milled upon the request and direction of ViroPharma. 

  

	 	(e)	Development Plan. “Development Plan” shall mean the development plan attached hereto as the Development Plan Exhibit. 

  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -3- 

	 	(f)	Initial Term. “Initial Term” shall mean the period of time required to complete Development Activities and the first five (5) years after Commercial
Manufacturing Initiation. 

  

	 	(g)	Lilly. “Lilly” shall mean Eli Lilly and Company. 

  

	 	(h)	Manufacturing Price. “Manufacturing Price” shall mean the price set forth in the Price Exhibit provided that, notwithstanding anything to the contrary, the
Manufacturing Price shall at all times be equal to or lower than any price for the Product offered by OSG Norwich to a third party. 

  

	 	(i)	Minimum Yield. “Minimum Yield” shall be the yield initially determined in Section 4 below. 

  

	 	(j)	PEG Specifications. “PEG Specifications” shall mean the specifications for testing the Polyethylene Glycol, or “PEG”, set forth in the Quality Agreement.

  

	 	(k)	Product. “Product” shall mean various presentations of the finished product containing Active Ingredient set forth in Specifications Exhibit attached in the Quality
Agreement and incorporated herein by reference known under the registered trademark Vancocin. 

  

	 	(l)	Project Agreement No.1. “Project Agreement No. 1” shall mean that certain Project Agreement No.1 dated as of December 1, 2005 between OSG Norwich and
ViroPharma. 

  

	 	(m)	Quality Agreement. The “Quality Agreement” shall mean that certain Quality Agreement dated as of December 1, 2005 between OSG Norwich and ViroPharma.

  

	 	(n)	Specifications. “Specifications” shall mean the specifications for Manufacturing and testing the Product set forth in Specifications Exhibit.

  

	 	(o)	Specifications Exhibit. “Specifications Exhibit” shall mean the exhibit to the Quality Agreement that sets for the specifications for Manufacturing and
testing the Product. 

  

	 	(p)	Territory. “Territory” shall mean the fifty (50) states and the District of Columbia and any territories and commonwealths constituting the United States of
America, including Puerto Rico. 

  

	 	2.	Development Activities. 

 In order for OSG Norwich
to start the Manufacture of the Product for ViroPharma, it will be necessary that the activities listed in the Development Plan be completed. The responsibilities of each of OSG Norwich and ViroPharma in relation to the Development Plan, and the
timeframes for completion of the Development Plan, are also set forth in the Development Plan. [***] shall pay OSG Norwich the fees designated in the Price Exhibit under the heading Development Activity Costs (“Development Costs”). OSG

  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -4- 

 Norwich acknowledges that the Development Costs represent OSG Norwich’s entire compensation for
performance of activities related to completion of the Development Plan. The parties agree to make commercially reasonable efforts to continue to complete the Development Plan in accordance with its terms. 
 OSG Norwich and ViroPharma acknowledge that certain development activities may be required in connection with API that is received from any source other
than Alpharma, Inc. (“Third Party API”). OSG Norwich and ViroPharma shall meet to discuss in good faith the parameters of such development activities, including timelines and cost. OSG Norwich shall not commence any work using the Third
Party API without ViroPharma’s prior written approval. 
 Subject to the terms and conditions set forth herein, ViroPharma hereby grants
to OSG a limited, non-exclusive, royalty free license under ViroPharma’s Patents and, ViroPharma’s Know-How relating to the manufacture of Product (the “Manufacturing Process Technology”), with no right to sublicense or assign
such licensed rights, solely for the purpose of performing OSG’s obligations under this Project Agreement, which are limited solely to manufacturing Product for and selling Product to ViroPharma, and any incidental purposes related thereto
solely for the benefit of ViroPharma. OSG and ViroPharma acknowledge and agree that (a) without limiting the generality of the foregoing, OSG shall not have any rights under the Manufacturing Process Technology to develop, manufacture or sell
Product or any other product for any party other than ViroPharma; (b) the Manufacturing Process Technology is, in whole and in part, the Confidential Information of ViroPharma; and (c) prior to and since November 9, 2004, Lilly has
been providing the Manufacturing Process Technology to OSG as a Representative of ViroPharma, and that it is the parties’ intention that, since such date, OSG has been operating solely in accordance with the license granted herein. 

 

	 	3.	Equipment Purchase. 

 In order for OSG Norwich to
manufacture Product for ViroPharma, ViroPharma has purchased certain Equipment (as defined in the Price Exhibit), and anticipates purchasing additional Equipment during the term of this Project Agreement, that is required for use by OSG in the
Manufacturing process. OSG Norwich agrees to purchase and install for ViroPharma all necessary Equipment. OSG Norwich shall maintain the Equipment in good working condition and in a manner consistent with industry practices and insured in the
ordinary course of business. 
 OSG Norwich shall inform ViroPharma in writing sixty (60) days prior to utilizing installed Equipment and
capital for manufacturing of any material other than Product, which use shall be additionally subject to this Section 3 and Section 4 below. Manufacturing of penicillin, cephalosporin, cytotoxic, or highly potent material on the installed
Equipment and capital is not permitted. Validated cleaning methods shall be established for all other materials. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -5- 

 Except as specifically set forth in this Project Agreement, OSG Norwich shall use the Equipment [***] to
manufacture the Product for ViroPharma, and shall not use the Equipment [***]. In the event that OSG Norwich wishes to use the equipment for the benefit of a third party during the [***] period following the successful completion of the validation
work described in this Project Agreement, ViroPharma [***], subject to the limitations and restrictions set forth in this Project Agreement. If, in [***], ViroPharma decides not to permit such use of the Equipment by OSG, then in the event that this
Project Agreement [***], or if this Project Agreement [***], OSG Norwich shall ship the Equipment to ViroPharma within [***] days. 
 If, in
[***], ViroPharma decides to permit the use of the Equipment by OSG for the benefit of a third party, then: 
 a. In the event
that [***], OSG Norwich shall a) return the Equipment to ViroPharma if OSG Norwich has no product under contract utilizing the Equipment or b) reimburse to ViroPharma [***] of the cost of an equivalent Equipment if OSG Norwich has product under
contract utilizing the Equipment; and 
 b. In the event that [***] OSG Norwich shall a) return the Equipment if OSG Norwich
has no product under contract utilizing the Equipment or b) retain title to the Equipment if OSG Norwich does have product under contract utilizing the Equipment. 
 Title to equipment and installed capital other than (a) the Equipment, and (b) any additional equipment used by OSG Norwich that is paid for by ViroPharma, will remain with OSG Norwich. 
  

	 	4.	Manufacture of Product. 

 Manufacture and
Purchase 
 Subject to the terms and conditions of this Project Agreement, the Agreement, the Quality Agreement, and the batch records
approved by ViroPharma, and beginning on the Commencement Date, OSG Norwich shall manufacture from Active Pharmaceutical Ingredient and supply to ViroPharma, and ViroPharma shall purchase from OSG Norwich, Product for commercial sale in the
Territory. 
 Except as provided below, during the period that OSG Norwich’s “Product Manufacturing Capacity” (as defined
below) equals or exceeds ViroPharma’s commercial requirements for finished cartons of the Product (as reflected in the first [***] Calendar Quarters of ViroPharma’s most recent forecast for the Product delivered to OSG Norwich pursuant to
Section 4.1(b) of the Agreement, the “Commercial Requirements”), ViroPharma shall purchase at least [***] of its Commercial 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -6- 

 Requirements for Product in the Territory during each such [***] Calendar Quarter period exclusively from
OSG Norwich, provided that,: 
 (a) without regard to the Product Manufacturing Capacity: 
 (i) if OSG Norwich is unable to meet the purchase orders of ViroPharma with respect to quantity ordered, quality of the Product and time
for delivery (assuming that such purchase orders meet the terms of this Project Agreement and the Master Agreement), then ViroPharma may obtain [***] of Product from a third person; 
 (ii) OSG Norwich acknowledges that, at any time, ViroPharma shall have the right to qualify [***] third party suppliers to manufacture the
Product and that ViroPharma is permitted to purchase up to [***] of its Commercial Requirements for Product in the Territory from such other third party suppliers; and 
 (iii) ViroPharma may purchase in excess of [***] of its Commercial Requirements for the Product from Lilly through [***]; and 

(b) during any period that OSG Norwich’s Product Manufacturing Capacity is less than ViroPharma’s Commercial Requirements for
the Product, ViroPharma may submit purchase orders for Product to, or otherwise obtain Product from, a third person in an amount not to exceed [***]. 
 Prior to the Commencement Date, prior to each anniversary of the Commencement Date, and at any time (not to exceed [***] each calendar year) that OSG Norwich, in good faith, reasonably determines that it has increased
its Product Manufacturing Capacity by at least [***], ViroPharma and OSG Norwich shall meet and mutually agree in writing on the number of capsules of the Product that OSG Norwich can Manufacture for ViroPharma during the [***] Calendar Quarter
period following the Commencement Date, each anniversary thereof, or such other time described in the beginning of this paragraph, as applicable (the “Number of Capsules”). If, within fifteen calendar days following the date that the
parties meet to determine the Number of Capsules, the parties cannot agree on the Number of Capsules, the matter shall be submitted to arbitration. The parties shall mutually agree on the selection of the arbitrator. If the parties cannot so agree
within 5 business days after the expiration of the foregoing fifteen calendar day, each party shall select one arbitrator and the two arbitrators shall be instructed to agree on a third arbitrator within five calendar days (the “Selected
Arbitrator”). Within five business days after the appointment of the Selected Arbitrator, each of the parties shall submit in writing to the Selected Arbitrator its calculation of the Number of Capsules and its reasoning in support thereof
(each, a “Written Proposal”), and the Selected Arbitrator shall be required to make a final determination by choosing one of the parties’ proposed Number of Capsules. The decision of the Selected Arbitrator in any such arbitration
shall be final, binding and not appealable. Each Party shall pay its own expenses of arbitration and the expenses of the arbitrators shall be equally shared by the parties. This arbitration provision shall be deemed to be self-executing, and in the
event either party fails to submit timely its Written Proposal, then the Selected Arbitrator shall select the Number of Capsules stated in the other party’s Written Proposal. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -7- 

 OSG Norwich: 
 (a) shall supply Product (including any other product containing the API) in the Territory exclusively to ViroPharma, except that OSG Norwich may continue to supply Product to Lilly to fulfill Lilly’s needs
outside of the Territory in [***]; 
 (b) shall not supply Product, or any product containing the API, anywhere in the world to any third
person other than to (i) Lilly to fulfill Lilly’s needs in [***] or (ii) any assignee of Lilly’s rights and obligations in [***] under its Master Agreement with OSG Norwich dated March 13, 2003 (as amended as of
August 31, 2004) and its Project Agreement with OSG Norwich dated August 31, 2004 to fulfill such assignees needs in [***]; 
 (c)
if ViroPharma decides to permit the use of the Equipment by OSG for the benefit of a third party as described in Section 3 above, then OSG Norwich shall, at all times, ensure that ViroPharma’s orders for Product are filled to the fullest
extent of the capacity of the Equipment, and shall not reject or reschedule for later delivery (in whole or in part), any order for Product from ViroPharma, due to limitations or restrictions that might otherwise arise relating to OSG Norwich’s
use of the Equipment for third parties; and 
 (d) shall provide ViroPharma in writing, within 5 business days after the end of each month,
data describing the amount of PEG in OSG’s possession at the end of the immediately preceding month. 
 Minimum Yield 

The Minimum Yield for the first [***] lots (excluding validation lots) of 125mg and 250mg presentations of the Product shall be [***]% of Theoretical
Carton Yield per batch (the “Initial Minimum Yield”). The “Theoretical Carton Yield” shall be determined by dividing (a) the Theoretical Capsule Yield by (b) [***]. The “Theoretical Capsule Yield” shall
be determined by dividing (y) the [***] used to produce a single batch of Product by (z) the [***] of Product. If the Actual Yield for the first [***] lots (excluding validation lots) of 125mg and 250mg presentations of the Product is less
than the Initial Minimum Yield, and if it determined that failure to meet Initial Minimum Yield is a direct result of OSG error, then OSG shall reimburse to ViroPharma an amount equal to (a) [***], times (b) the [***]. At ViroPharma’s
option, reimbursement shall be made to ViroPharma as a set off against invoices that ViroPharma owes OSG, or against future invoices related to the Product.
 Following the manufacture of the first [***] lots (excluding validation lots) of 125mg and 250mg presentations of the Product under this Project Agreement, the “Minimum Yield” will be established and agreed
between ViroPharma and OSG, and thereafter the Minimum Yield will be subject to the provisions of section of 5.4 of the Agreement. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -8- 

 The Supplier Relationship Team may change the Minimum Yield from time to time, as circumstances require
by doing so in writing. An authorized representative of each Party must sign any setting of the Minimum Yield. 
  

	 	5.	Manufacturing Price. 

 ViroPharma shall pay to OSG
Norwich, and OSG Norwich shall accept from ViroPharma, the Manufacturing Price designated in Price Exhibit as OSG Norwich’s total compensation for Manufacture of Product, including all labor, materials, facilities, equipment, services, taxes,
overhead, and profit.
 The Manufacturing Price designated in Price Exhibit consists of two (2) components: “Materials
Costs” and “Non-Materials Costs.” The “Materials Costs” set forth on the Price Exhibit shall equal OSG Norwich’s actual out-of-pocket costs to acquire the materials described on the OSG Materials Exhibit attached
hereto (“Materials”), and the Materials Costs described on the Price Exhibit shall include a handling fee equal to [***] of such out-of pocket costs. The Materials Costs shall initially be as set forth in the Price Exhibit, and shall
remain firm for Product shipped prior to and during the [***] period of time after Commercial Manufacturing Initiation (such [***] period, and each subsequent [***] period, a “Commercial Manufacturing [***]”). Following the first
Commercial Manufacturing [***] hereunder, OSG Norwich may, in accordance with the procedure set forth below, notify ViroPharma [***] in each Commercial Manufacturing [***] of any changes in the Manufacturing Price due to changes in Materials Costs,
such increase in Materials Costs not to exceed in any year OSG’s actual out-of-pocket costs to acquire the Materials plus a handling fee equal to [***] of such out-of pocket costs.
 The “Non-Materials Costs” shall be all other components of the Manufacturing Price other than the Materials Costs. The Non-Materials Costs
shall initially be as set forth in the Price Exhibit, and shall remain firm for Product shipped prior to and during [***] Commercial Manufacturing [***] hereunder. Following the [***] Commercial Manufacturing [***] hereunder, OSG Norwich may,
in accordance with the procedure set forth below, notify ViroPharma [***] in each Commercial Manufacturing [***] of any changes in the Manufacturing Price due to changes in Non-Materials Costs, such increase in Non-Materials Costs not to exceed in
any year the CPI-Adjusted Amount. The “CPI Adjusted Amount” shall be determined by multiplying the then-current Non-Materials Costs by a fraction, (i) the numerator of which shall be equal to the difference between the Index for the
calendar month immediately preceding the last month of the then-current Commercial Manufacturing [***], less the Index for that same calendar month in the immediately preceding Commercial Manufacturing [***] (the “Previous Index”), and
(ii) the denominator of which shall be equal to the Previous Index. For the purposes 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -9- 

 hereof, the term “Index” means the Consumer Price Index published by the Bureau of Labor
Statistics of the U.S. Department of Labor for all Urban Consumers (CPI-U) — U.S. All Items (1982-1984 = 100). In the event that the compilation and/or publication of the Index shall be transferred to any other governmental department,
bureau, or agency, or shall be discontinued, then the index most similar to the Index shall be used. 
 No changes to the Manufacturing Price
shall be effective unless OSG Norwich delivers proper notice of any changes to the Materials Costs and/or Non-Materials Costs, computed in accordance with the provisions set forth above and with accompanying documentation setting forth such
computations in reasonable detail, to ViroPharma at least [***] days prior to the expiration of the then-current Commercial Manufacturing [***]. Changes in the Manufacturing Price will be effective for all Product shipped by OSG Norwich in the
following Commercial Manufacturing [***].
 Invoicing and payment shall be in United States dollars and shall follow the procedures set forth
in the Agreement. 
 The compensation for and development of ongoing stability testing is listed as Stability Costs in the Price Exhibit
(“the “Stability Costs”). ViroPharma shall pay [***] Stability Costs. The Stability Costs shall remain firm for stability services invoiced during the [***] year period of time after Commercial Manufacturing Initiation. 
 Upon ViroPharma’s request, OSG Norwich shall provide to ViroPharma a written estimate of any increase in cost in Manufacturing Product that may be
caused by a change in the PEG Specifications. Any increase in cost experienced by OSG Norwich in Manufacturing Product for ViroPharma that is directly related to changes in the PEG Specifications required by ViroPharma shall be passed on to
ViroPharma. 
  

	 	6.	Shelf Life and Storage Requirements. 

 Subject at
all times to the limitations on OSG Norwich’s obligations described in Section 18 of the Agreement (Force Majeure), Product shipped to ViroPharma or to other locations of ViroPharma’s designation shall meet the following shelf life
and storage requirements: 
  

			
	Shelf Life:	  	Minimum of [***] to [***] months remaining at time of shipment.
		
	Storage Requirements:	  	The handling and storage conditions for finished Product are Controlled Room Temperature, which is equivalent to 15 to 30 C (59 to 86 F) (Note: refer to Quality Agreement for storage conditions
of Vancomycin HCl).

  

	 	7.	Term. 

 This Project Agreement shall be effective as
of the Project Agreement Effective Date and shall expire on the fifth (5th) anniversary of Commercial
Manufacturing Initiation. At the 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -10- 

 end of the Project Agreement Initial Term, this Project Agreement shall continue automatically for
successive [***] periods under the same terms and conditions hereunder until terminated. This Project Agreement may be terminated by ViroPharma at the expiration of the Project Agreement Initial Term or at the expiration of any renewal term upon not
less than [***] months prior written notice to OSG Norwich. OSG Norwich may terminate this Project Agreement at the expiration of the Project Agreement Initial Term or at the expiration of any renewal term upon not less than [***] months prior
written notice to ViroPharma. In addition to the foregoing, either Party may terminate this Project Agreement in the event of a material breach by the other Party of this Project Agreement, provided that the Party asserting such breach first serves
written notice of the alleged breach on the offending Party and such breach is not cured within [***] days of said notice; provided further, however, that this Project Agreement shall not terminate in the event of a material breach pursuant to this
Section 7 unless, at the termination of such [***] day period, the Party asserting such breach notifies the other Party in writing of such termination due to a failure to cure the material breach. 
  

	 	8.	Project Agreement No. 1 

 Notwithstanding
anything to the contrary in Project Agreement No. 1, from and after the Commencement Date: (a) all matters relating to ViroPharma’s obligations to purchase Product from OSG Norwich shall be governed by this Project Agreement, and
(b) all of such obligations of ViroPharma under Project Agreement No. 1 shall automatically terminate, except with respect to purchase orders delivered to, and accepted by, OSG prior to the Commencement Date in respect of Product intended
by the parties to be Manufactured by OSG Norwich and delivered to ViroPharma under Project Agreement No. 1. Notwithstanding the foregoing, if ViroPharma requests OSG Norwich to manufacture Product in the small tank under Project Agreement
No. 1, or if Product must be manufactured under Project Agreement No. 1 because the large tank used for this Project Agreement is available as a result of [***] event as defined in paragraph [***] of the Agreement, then the prices for such
Product will be as listed in the Price Exhibit in Project Agreement No. 1 . Any termination of this Project Agreement shall automatically terminate Project Agreement No. 1, unless the parties otherwise agree in writing to continue the
effectiveness of Project Agreement No. 1. 
  

	 	9.	Entire Agreement. 

 This Project Agreement, the
Agreement, and the Quality Agreement, including the exhibits and other attachments hereto and thereto, contain the entire agreement between the parties relating to the subject hereof and supersedes all prior drafts or understanding, whether written
or oral, relating to the subject matter hereof. 
  

	 	10.	Amendment. 

 Except as otherwise provided herein,
this Project Agreement, including the exhibits and other attachments hereto, may be modified or amended only by written agreement of the Parties hereto signed by authorized representatives of the Parties. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -11- 

 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -12- 

 IN WITNESS WHEREOF, the Parties have caused this Project Agreement to be executed and delivered on the date first set
forth above. 
 VIROPHARMA INCORPORATED 
  

			
	By:	 	 /s/ Michel de Rosen

	Printed Name:	 	Michel de Rosen
	Title:	 	Chief Executive Officer

 OSG NORWICH PHARMACEUTICALS, INC. 
  

			
	By:	 	 /s/ Christopher R. Calhoun

	Printed Name:	 	Christopher R. Calhoun
	Title:	 	President

  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -13- 

 PRICE EXHIBIT 
 PRODUCT: Vancocin capsules 
 MATERIALS: 
  

	 	 ̈	ViroPharma Supplied: Vancomycin Hydrochloride API, and Polyethylene Glycol (PEG). 

  

	 	 ̈	OSG Norwich Supplied: All other materials required for manufacturing and packaging. 

  

			
	TERMS:	  	Net [***] days
		
	FOB:	  	[***]
		
	PALLETS:	  	[***] each for OSG Norwich supplied pallets used to ship Product.

 MANUFACTURING PRICE: 
 Vancocin Capsules 125 mg and 250 mg: 
  

	 	1.	125 mg: 

  

					
	 Non-Materials Costs per
 finished carton of Product
	 	 Materials Costs per
 finished carton of Product
	 	 Manufacturing Price per
 finished carton of Product

	[***]	 	[***]	 	[***]

  

	 	2.	250 mg: 

  

					
	 Non-Materials Costs per
 finished carton of Product
	 	 Materials Costs per
 finished carton of Product
	 	 Manufacturing Price per
 finished carton of Product

	[***]	 	[***]	 	[***]

 For clarity, each finished carton of Product shall contains [***] blister packs of [***] capsules of Product, and
the total cost per finished carton of Product includes the costs for [***]. The Manufacturing Price per finished carton of Product shall at all times be [***]. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -14- 

 DEVELOPMENT ACTIVITY COSTS 
 Development Lots, Validation Lots and Stability 
 As more fully described in the Development Plan, OSG Norwich shall Manufacture [***]
development lot of each of the 125 mg and 250 mg presentations of the Product, and [***] validation lots of each of the 125 mg and 250 mg presentations of the Product. 
 Completion of stability tests for the initial time points for all development and validation lots are included in Process Qualification and IOQ charges. Additional stability costs for Development Activities will be
charged on a [***] pull price. Stability charges for this Product shall be invoiced at the completion of stability testing and documentation. The following stability table outlines the project stability requirements and estimated charges.

 Development Lots: 
 Estimated charge for Manufacturing both development lots equals [***]. 
 Validation Lots: 
 Stability: 
  

	 	•	 	[***]: 

 The [***] lots of each strength
will utilize [***] 
 Estimated charge for stability pulls associated with the validation lots equals [***]. 
 Manufacturing: 
 Estimated
charge for Manufacturing all validation lots equals [***] 
 Product made in the [***] demonstration and [***] validation lots and that remains after testing
associated with the validation plan will be reimbursed at the per carton Manufacturing Price when made available for commercial sale. 
 Cleaning
Validation/Verification 
 Estimated charge equals [***] 
 [***] 
 Estimated charge equals [***] 
 EQUIPMENT: 
 ViroPharma shall purchase or reimburse OSG Norwich for the following equipment/services required to manufacture the Product. The equipment described below is the “Equipment” referred to in this Project Agreement. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -15- 

					
	 Type
	  	 	  	Cost
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
	 [***]
	  	[***]	  	[***]
		  		  	 
	 TOTAL
	  		  	[***]
		  		  	 

	*	purchased by ViroPharma for use by OSG Norwich prior to the date of this Project Agreement 

 REFERENCE STANDARD MANAGEMENT 
 OSG Norwich shall manage the reference standards for
Third Party API at no additional cost to ViroPharma. 
 STABILITY COSTS FOLLOWING “COMMERCIAL MANUFACTURING INITIATION”: 
 Cost per Pull: [***]. “Pull” is defined as testing and documenting results of required analytical methods as required in the Product
Specification for one sample for one time point for each condition. 
 Stability Table: The following are the estimated requirements
for the stability program for this Product. Stability charges for this Product shall be invoiced at the time of the completion of stability testing and documentation. 
 Annual Routine Pulls: A minimum of [***] lot of each strength per year for a total of [***] lots per year

 [***] 
 Total estimated cost per year = [***] 
 Non-routine Stability Request: In the event of a deviation, or an event
requiring further investigation, either party may request an additional stability study. OSG Norwich and ViroPharma shall discuss in good faith the event leading to the request. In the event that the deviation is clearly the result of fault of OSG
Norwich, OSG Norwich shall be responsible for costs associated for related stability pulls. In the event that the cause of the deviation is not clearly due to the fault of OSG Norwich, then the parties shall discuss in good faith the responsibility
of costs associated for related stability pulls. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -16- 

 DEVELOPMENT PLAN EXHIBIT 
 Except as set forth on the attached Schedule of Exceptions, Lilly has previously supplied OSG Norwich with the following information: 
  

	 	1.	Process flow chart 

  

	 	2.	Process flow document 

  

	 	3.	Development history reports 

  

	 	4.	Existing stability protocols for drug product 

  

	 	5.	In-process control methods 

  

	 	6.	Master Formulas of Indianapolis registration stability lots with Alpharma vancomycin hydrochloride 

  

	 	7.	Raw material specifications 

  

	 	8.	Raw material suppliers 

  

	 	9.	Drug product specifications 

  

	 	10.	Health and safety information 

  

	 	11.	Analytical Methods 

  

	 	12.	Analytical Transfer Protocols 

  

	 	13.	Cleaning Method Protocol 

 OSG Norwich
has completed the following activities prior to start of validation: 
 [***] 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -17- 

 DEVELOPMENT PLAN EXHIBIT (continued) 
 OSG Norwich has transferred the following methods prior to validation: 
  

			
	 Method
	  	Used For
	 [***]
	  	[***]

 OSG Norwich will manufacture the following type and number of lots for the
described purpose: 
 [***] 
 OSG Norwich will complete the following activities in order to consider the scale-up validation effort to be complete: 
 [***] 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -18- 

 SCHEDULE OF EXCEPTIONS 
 None. 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. 

  

 -19- 

 MATERIALS EXHIBIT 
 Provided by OSG Norwich: 
 [***] 
  

	[***]	Indicates material that has been omitted and for which confidential treatment has been requested. All such omitted material has been filed with the Securities and Exchange
Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.Second Amended and Restated

 Exhibit 10.1 
 AMERICAN SUPERCONDUCTOR CORPORATION 
 SECOND AMENDED AND RESTATED 1997 DIRECTOR 
 STOCK OPTION PLAN, AS AMENDED 
 1. Purpose.

 The purpose of this Second Amended and Restated 1997 Director Stock Option Plan, as amended (the “Plan”), of American
Superconductor Corporation (the “Company”) is to encourage stock ownership in the Company by outside directors of the Company whose continued services are considered essential to the Company’s future success and to provide them with a
further incentive to remain as directors of the Company. 
 2. Administration. 
 The Board of Directors shall supervise and administer the Plan. Grants of stock options and stock awards under the Plan and the amount and nature of the
options and awards to be granted shall be automatic in accordance with Section 5. However, all questions concerning interpretation of the Plan or any options or awards granted under it shall be resolved by the Board of Directors and such
resolution shall be final and binding. No director or person acting pursuant to the authority delegated by the Board of Directors shall be liable for any action or determination relating to or under the Plan made in good faith. 
 3. Participation in the Plan. 
 Directors of the Company who are not full-time employees of the company or any subsidiary of the Company (“Outside Directors”) shall be eligible to receive options and stock awards under the Plan, except
that Directors of the Company who are representatives of an equity holder of the Company shall not be eligible to receive options or awards under the Plan. 
 4. Stock Subject to the Plan. 
  

	 	(1)	The maximum number of shares of the Company’s Common Stock, par value $.01 per share (“Common Stock”), which may be issued under the Plan shall be 790,000 shares,
subject to adjustment as provided in Section 7. 

  

	 	(2)	If any outstanding option under the Plan for any reason expires or is terminated without having been exercised in full, the shares covered by the unexercised portion of such option
shall again become available for issuance pursuant to the Plan. 

  

	 	(3)	All options granted under the Plan shall be non-statutory options not entitled to special tax treatment under Section 422 of the Internal Revenue Code of 1986, as amended (the
“Code”). 

  

	 	(4)	Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. 

 5. Terms, Conditions and Form of Options. 
 Each option granted under the Plan shall be evidenced by a written agreement in such form as the President or the Executive Vice President, Corporate
Development, shall from time to time approve, which agreements shall comply with and be subject to the following terms and conditions: 
  

	 	(a)	Option Grants and Stock Awards. 

  

	 	(i)	Initial Grants to Outside Directors. An option to purchase 20,000 shares of Common Stock shall be granted automatically to each Outside Director first elected to the Board of
Directors after the date of the approval of the Plan by the stockholders of the Company, upon the date of his or her initial election to the Board of Directors. 

  

	 	(ii)	Stock Awards to Outside Directors. An award of 5,000 shares of Common Stock shall be granted automatically, on the third business day following the date of each Annual Meeting
of Stockholders of the Company, to each person serving as an Outside Director of the Company on the date of such grant, provided that such Outside Director has served on the Board of Directors of the Company for at least one full calendar year prior
to the date of such grant. The shares of Common Stock covered by such award shall be fully vested and not subject to any repurchase rights or other contractual restrictions. 

  

	 	(b)	Option Exercise Price. The option exercise price per share for each option granted under the Plan shall be equal to the fair market value per share of Common Stock on
the date of grant, which shall be determined as follows: (i) if the Common Stock is listed on the Nasdaq National Market or another nationally recognized exchange or trading system as of the date on which a determination of fair market value is
to be made, the fair market value per share shall be deemed to be the last reported sale price per share of Common Stock thereon on such date (or, if no such price is reported on such date, such price on the nearest preceding date on which such a
price is reported); and (ii) if the Common Stock is not listed on the Nasdaq National Market or another nationally recognized exchange or trading system as of the date on which a determination of fair market value is to be made, the fair market
value per share shall be as determined by the Board of Directors. 

  

	 	(c)	Transferability of Options. Except as the Board of Directors may otherwise determine, options shall not be sold, assigned, transferred, pledged or otherwise encumbered
by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the optionee, shall be exercisable only by the optionee. References to a optionee, to
the extent relevant in the context, shall include references to authorized transferees, if any. 

	 	(d)	Vesting Period. 

  

	 	(i)	General. Each option granted pursuant to Section 5(a)(i) shall become exercisable in equal annual installments over a two year period following the date of grant.

  

	 	(ii)	Acceleration Upon An Acquisition Event. Notwithstanding the foregoing, each outstanding option granted pursuant to Section 5(a)(i) shall immediately become exercisable in full
in the event an Acquisition Event (as defined in Section 8) of the Company occurs. 

  

	 	(e)	Termination. Each option shall terminate, and may no longer be exercised, on the earlier of the (i) the date ten years after the date of grant or (ii) the date 60
days after the optionee ceases to serve as a director of the Company for any reason, whether by death, resignation, removal or otherwise. 

  

	 	(f)	Exercise Procedure. Options may be exercised only by written notice to the Company at its principal office accompanied by (i) payment in cash or by certified or bank
check of the full consideration for the shares as to which they are exercised or (ii) an irrevocable undertaking, in form and substance satisfactory to the Company, by a broker to deliver promptly to the Company sufficient funds to pay the
exercise price or (iii) delivery of irrevocable instructions, in form and substance satisfactory to the Company, to a broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price. 

  

	 	(g)	Exercise by Representative Following Death of Director. An optionee, by written notice to the Company, may designate one or more persons (and from time to time change such
designation), including his or her legal representative, who, by reason of the optionee’s death, shall acquire the right to exercise all or a portion of the option. If the person or persons so designated wish to exercise any portion of the
option, they must do so within the term of the option as provided herein. Any exercise by a representative shall be subject to the provisions of the Plan. 

 6. Limitation of Rights. 
  

	 	(a)	No Right to Continue as a Director. Neither the Plan, nor the granting of an option nor any other action taken pursuant to the Plan, shall constitute or be evidence of any
agreement or understanding, express or implied, that the optionee shall be entitled to continue as a director for any period of time. 

  

	 	(b)	No Stockholder Rights for Options. An optionee shall have no rights as a stockholder with respect to the shares covered by his or her option until the date of the issuance to
him or her of a stock certificate therefor, and no adjustment will be made for dividends or other rights (except as provided in Section 7) for which the record date is prior to the date such certificate is issued. Notwithstanding the foregoing,
in the event the Company effects a split of the Common Stock by means of a stock dividend, and the distribution date (i.e., the date on which the 

 closing market price of the Common Stock on a stock exchange or trading system is adjusted to reflect the
split) is subsequent to the record date for such stock dividend, an optionee who exercises an option between the close of business on such record date and the close of business on such distribution date shall be entitled to receive the stock
dividend with respect to the shares of Common Stock acquired upon such option exercise, notwithstanding the fact that such shares were not outstanding as of the close of business on such record date. 
  

	 	(c)	Compliance with Securities Laws. Each option and stock award shall be subject to the requirement that if, at any time, counsel to the Company shall determine that the
listing, registration or qualification of the shares subject to such option or stock award upon any securities exchange or under any state or federal law, or the consent or approval of any governmental or regulatory body, or the disclosure of
non-public information or the satisfaction of any other condition is necessary as a condition to, or in connection with, the issuance or purchase of shares thereunder, such option may not be exercised, in whole or in part, and such stock award shall
not be granted, unless such listing, registration, qualification, consent or approval, or satisfaction of such condition shall have been effected or obtained on conditions acceptable to the Board of Directors. 

 7. Adjustment to Common Stock. 
 In the event of any stock split, stock dividend, recapitalization, reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off or other similar change in capitalization or event, or
any distribution to holders of Common Stock other than a normal cash dividend, (i) the number and class of security available under this Plan, (ii) the number and class of security covered by future option grants and stock awards under
Section 5(a) and (iii) the number and class of security and exercise price per share subject to each outstanding option shall be appropriately adjusted by the Company to the extent the Board shall determine, in good faith, that such an
adjustment is necessary and appropriate. No fractional shares will be issued under the Plan on account of any such adjustments. If this Section 7 applies and Section 8 also applies to any event, Section 8 shall be applicable to such
event and this Section 7 shall not be applicable. 
 8. Acquisition Events. 
 Upon the occurrence of an Acquisition Event (as defined below), or the execution by the Company of any agreement with respect to an Acquisition Event, the
Board shall take any one or more of the following actions with respect to then outstanding options: (i) provide that outstanding options shall be assumed, or equivalent options shall be substituted, by the acquiring or succeeding corporation
(or an affiliate thereof), provided that any such options substituted for such options shall satisfy, in the determination of the Board, the requirements of Section 424(a) of the Internal Revenue Code of 1986, as amended; (ii) upon written
notice to the optionees, provide that all then unexercised options will become exercisable in full as of a specified time (the “Acceleration Time”) prior to the Acquisition Event and will terminate immediately prior to the consummation of
such Acquisition Event, except to the extent exercised by the optionees between the Acceleration Time and the consummation of such Acquisition Event; and (iii) in the event of an Acquisition 

 Event under the terms of which holders of Common Stock will receive upon consummation thereof a cash
payment for each share of Common Stock surrendered pursuant to such Acquisition Event (the “Acquisition Price”), provide that all outstanding options shall terminate upon consummation of such Acquisition Event and each optionee shall
receive, in exchange therefor, a cash payment equal to the amount (if any) by which (A) the Acquisition Price multiplied by the number of shares of Common Stock subject to such outstanding options (whether or not then exercisable), exceeds
(B) the aggregate exercise price of such options. 
 An “Acquisition Event” shall mean: (x) any merger or consolidation
which results in the voting securities of the Company outstanding immediately prior thereto representing immediately thereafter (either by remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less
than 50% of the combined voting power of the voting securities of the Company or such surviving or acquiring entity outstanding immediately after such merger or consolidation; (y) any sale of all or substantially all of the assets of the
Company; or (z) the complete liquidation of the Company. 
 9. Modification, Extension and Renewal of Options.

 The Board of Directors shall have the power to modify or amend outstanding options; provided, however, that no modification or amendment
may (i) have the effect of altering or impairing any rights or obligations of any option previously granted without the consent of the optionee, or (ii) modify the number of shares of Common Stock subject to the option (except as provided
in Section 7). 
 10. Termination and Amendment of the Plan. 
 The Board of Directors may suspend, terminate or discontinue the Plan or amend it in any respect whatsoever; provided, however, that without approval of
the stockholders of the Company, no amendment may (i) increase the number of shares subject to the Plan (except as provided in Section 7), or (ii) effect any action which requires approval of the stockholders pursuant to the rules or
requirements of the Nasdaq National Market or any other exchange on which the Common Stock of the Company is listed. 
 11.
Notice. 
 Any written notice to the Company required by any of the provisions of the Plan shall be addressed to the Treasurer of the
Company and shall become effective when it is received. 
 12. Governing Law. 
 The Plan and all determinations made and actions taken pursuant hereto shall be governed by the laws of the State of Delaware. 

 13. Stockholder Approval. 
 The Plan is conditional upon stockholder approval of the Plan within one year from its date of adoption by the Board of Directors, and no option may be
granted under the Plan until such stockholder approval is obtained. 
  

	
	First adopted by the Board of Directors on July 24, 1997 and approved by the stockholders on September 5, 1997
	
	Amended and Restated Plan adopted by the Board of Directors on May 2, 2000 and approved by the stockholders on July 28, 2000
	
	Second Amended and Restated Plan adopted by the Board of Directors on April 25, 2002 and approved by the stockholders on July 26, 2002
	
	Second Amended and Restated Plan, as amended, adopted by the Board of Directors on May 6, 2004 and approved by the stockholders on July 29, 2004
	
	Second Amended and Restated Plan, as amended, adopted by the Board of Directors on May 4, 2006 and approved by the stockholders on July 27, 2006.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]